Dysmenorrhea Treatment Survey and 2027 Foresight Report

Posted April 21, 2017 by shivkumar

Dysmenorrhea Treatment Market, by Application (Hospital, Pharmaceutical), by Type (Primary, Secondary), by Treatment (NSAIDs, Hormonal, Non-steroidal anti-inflammatory drugs) - Forecast 2027
Dysmenorrhea Treatment: Market Overview

Globally, more than 50% of post pubescent menstruating women are affected by dysmenorrhea, with 10–12% of them having severe dysmenorrhea with incapacitation for 1–3 days each month. Because young women constitute a significant percentage of the adult work force in the US, nearby 600 million working hours or 2 billion dollars are lost annually because of incapacitating dysmenorrhea if adequate relief is not provided. Women who continue to work or to attend classes have been shown to have lower work output or scores during their dysmenorrhea.

Dysmenorrhea is characterized as recurrent pelvic pain associated with menstruation. Dysmenorrhea is the most well-known gynecologic dissension in adolescents, happening in 60-93% of ladies in this demographic congregation. It is more predominant amid late youthfulness, with the start of ovulatory cycles a few years after the beginning of menstruation. Crest occurrence happens amid the late adolescent years and mid-20s.

Market Segmentation

The Global Dysmenorrhea Treatment Market can be segmented on the basis of types, treatment, and applications.

Global Dysmenorrhea Treatment Market by Types:

• Primary
• Secondary

Global Dysmenorrhea Treatment Market by Treatment methods:

• General Diagnosis

• Non-hormonal medical treatment
o Non-steroidal anti-inflammatory drugs (NSAIDs)
o Over-the-counter (OTC) medications

• Hormonal medical treatment
o Combined oral contraceptive
o Progestin regimens
o Levonorgestrel intrauterine system (LN-IUS)

• Surgical Treatment

Global Dysmenorrhea Treatment Market by Applications:

• Pharmaceuticals
• Hospitals
• Clinics

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/727

It is for the most part ordered into two general classes:

• Primary Dysmenorrhea alludes: to menstrual pain without any fundamental pelvic pathology.

• Secondary Dysmenorrhea alludes: to menstrual pain connected with a predefined organic etiology.

Symptoms of Dysmenorrhea include cramping pain in the midline in the suprapubic area, and may have associated backache, leg pains, nausea, vomiting, light-headedness and headache.

Market Application

The Dysmenorrhea is been treated by various methods such as with the help of medicines, with the help of high level treatment and in some severe cases surgeries is been preferred. Presently Transcutaneous electrical nerve stimulation (TENS) device is been used for the treatment of Dysmenorrhea.

Browse Report Details @ https://www.marketresearchfuture.com/reports/dysmenorrhea-treatment-market

Global Dysmenorrhea Treatment Market Major Players:

Some of the major players of Global Dysmenorrhea Treatment Market are as follows:

• Novartis Pharmaceuticals Corporation
• Merck, Inc.
• Bayer Schering Pharma AG
• Vanita Therapeutics, Alvogen, Pfizer, Inc.
• Roche Laboratories
• Taj Pharmaceuticals, Ltd.
• Sanofi
• Terramedic, Inc.

Latest Trends in Dysmenorrhea Treatment Market:

• Novartis receives three FDA Breakthrough Therapy Designations in 2016 for Ilaris to treat rare types of Periodic Fever Syndromes.

• Transcutaneous electrical nerve stimulation (TENS) is an established method for pain relief in Dysmenorrhea, which does not involve the use of medication.

Request Table of Contents for this Report @ https://www.marketresearchfuture.com/request-toc/727

Global Dysmenorrhea Treatment Market Regional Analysis:

The regional analysis includes North America, Europe, Asia Pacific, Middle East and rest of the world.

The Global Dysmenorrhea Treatment Market is expected to grow with a CAGR of more than 3% during the forecasted period due to high usage of low price OTC (over-the-counter) and off-label treatment.

North America:

The North America is dominating the Dysmenorrhea market followed by Europe due the existence of a large number of Dysmenorrhea patients in these regions. North America and European Dysmenorrhea market is driven by high healthcare spending, improved healthcare infrastructure and high awareness about the disease and high availability of its treatments.


Asia-Pacific is expected to have rapid growth in Dysmenorrhea market due to increase in purchasing power, changing healthcare infrastructure and increased awareness for clinical facilities in the regions such as India, China, Japan and others.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Akash Anand,
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Email: [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Akash Anand, Market Research Future
Country India
Categories Health , Medical , Science
Tags dysmenorrhea treatment industry , dysmenorrhea treatment market , global dysmenorrhea treatment market , hypertension drugs market share
Last Updated April 21, 2017